BridgeBio Pharma Inc (OQ:BBIO)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 421 Kipling St
PALO ALTO CA 94301-1530
Tel: N/A
Website: bridgebio.com
IR: See website
<
Key People
Neil Kumar
Chief Executive Officer, Director
Brian C. Stephenson
Chief Financial Officer
Charles J. Homcy
Chairman of Pharmaceuticals, Director
Richard Henry Scheller
Chairman of Research & Development, Director
Frank Mccormick
Chairman of Oncology
Michael Henderson
Senior Vice President - Asset Acquisition, Strategy and Operations
Cameron Turtle
Senior Vice President - Portfolio Management and Corporate Development
Uma Sinha
Chief Scientific Officer
 
Business Overview
BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company's product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company's pipeline programs include product candidates ranging from early discovery to late-stage development. The Company's products include BBP-265, BBP-831, BBP-631 and BBP-454.
Financial Overview
For the fiscal year ended 31 December 2019, BridgeBio Pharma Inc revenues increased from $0K to $40.6M. Net loss increased 99% to $260.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 47% to $204.3M (expense), General and administrative increase of 96% to $76.6M (expense).
Employees: 248 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $2,650M as of Dec 31, 2019
Annual revenue (TTM): $40.56M as of Dec 31, 2019
EBITDA (TTM): -$263.62M as of Dec 31, 2019
Net annual income (TTM): -$260.59M as of Dec 31, 2019
Free cash flow (TTM): -$258.73M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 123,765,465 as of Feb 24, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization